Zobrazeno 1 - 10
of 171
pro vyhledávání: '"A. Z. S. Rohatiner"'
Autor:
Gilles Salles, Ama Z. S. Rohatiner, Jelle W. Kylstra, Hervé Tilly, Barbara Botto, Pierre Soubeyran, Achiel Van Hoof, Angelika Bischof-Delaloye, Franck Morschhauser, Anton Hagenbeek, Wim L.J. van Putten, John Radford
Publikováno v:
Journal of clinical oncology, 31(16), 1977-1983. American Society of Clinical Oncology
Purpose Updated results are presented after a median follow-up of 7.3 years from the phase III First-Line Indolent Trial of yttrium-90 (90Y) –ibritumomab tiuxetan in advanced-stage follicular lymphoma (FL) in first remission. Patients and Methods P
Autor:
T. A. Lister, Peter MacCallum, J. A. L. Amess, Christopher D Dalley, Sarah Slater, Mike Bradburn, A. Z. S. Rohatiner, M. Carter, Debra M. Lillington
Publikováno v:
Hematology (Amsterdam, Netherlands). 6(3)
Between 1969 and 1999, 420 patients (age > 60 years) with newly diagnosed AML were managed at St Bartholomew's Hospital (SBH), London, UK. Sixty-nine percent of patients received therapy with curative intent Eighty-eight patients (31%) of the latter
Autor:
Ama Z. S. Rohatiner, Jane Stevens, Jude Fitzgibbon, Simon P. Joel, Christina Sieniawska, Shireen Kassam, Rachel Waters, Silvia Montoto, Andrew Lister
Publikováno v:
British Journal of Haematology. 154:448-456
Summary We have previously reported presentation serum selenium level to be predictive of outcome in diffuse large B–cell lymphoma. This has now been studied in a further 430 patients, 163 with acute myeloid leukaemia (AML), 156 with Hodgkin Lympho
Autor:
Shekhar Krishnan, Ama Z. S. Rohatiner, Finlay MacDougall, Tamara Intermesoli, Michael Jenner, Andrew Lister
Publikováno v:
Annals of Hematology. 90:1059-1065
Intensification of chemotherapy in adults with acute lymphoblastic leukemia (ALL) has improved outcome. The aim of this analysis was to evaluate outcome of patients treated with an intensive regimen based on that used in the German national trials, b
Publikováno v:
Hematological Oncology. 29:1-4
Our current knowledge of the epidemiology and treatment outcome of lymphoma in low-income countries is very limited. In the poorest countries only a small proportion of patients have access to treatment while clinical research is almost non-existent.
Autor:
Adrian C. Newland, Magnus Björkholm, Andrew Lister, Eros Di Bona, Jude Fitzgibbon, Finlay MacDougall, Francesco Rodeghiero, Renato Bassan, Ama Z. S. Rohatiner, Roberto Raimondi, Rachel Waters, Alessandro Rambaldi, Tiziano Barbui, Steve Johnson, Jamie Cavenagh, Orietta Spinelli, Matthew L. Smith
Publikováno v:
British Journal of Haematology. 167:724-726
Autor:
Andrew Lister, Silvia Montoto, Peter Johnson, John Radford, Jonathan P. Kerr, Hannah Hunter, Susan M Neeson, Sandra J. Strauss, Ama Z. S. Rohatiner, Simon Rule, Agathoclis Agathocleous, Janet Matthews
Publikováno v:
British Journal of Haematology. 151:346-353
The combination of bortezomib and rituximab was evaluated in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL) and Waldenstrom macroglobulinaemia (WM), in a Phase I and later, a randomized Phase II study. In the randomized study, 42
Autor:
Sameena Iqbal, Franck Morschhauser, Anton Hagenbeek, Karin E. Summers, Andrew Lister, Ama Z. S. Rohatiner, Barbara Putz, Jens Kuhlmann, Lindsey K. Goff, Tom Louton, Michael Kunz
Publikováno v:
Journal of clinical oncology, 27(36), 6094-6100. American Society of Clinical Oncology
Purpose The randomized First-Line Indolent Trial (FIT) was conducted in patients with advanced follicular lymphoma (FL), to evaluate the safety and efficacy of yttrium-90 (90Y) ibritumomab tiuxetan given as consolidation of complete or partial remiss
Autor:
Ama Z. S. Rohatiner, Fredrick B. Hagemeister, Martin Dreyling, Franck Morschhauser, Angelika Bischof Delaloye
Publikováno v:
The Oncologist. 14:17-29
Non-Hodgkin’s lymphoma (NHL) comprises both indolent forms, including follicular lymphoma (FL) and marginal zone lymphoma (MZL), and aggressive forms, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). FL and DLBCL are
Autor:
Nnenna Osuji, S. A. Johnson, Claire Dearden, Juan Garcia-Talavera, Monica Else, Estella Matutes, Daniel Catovsky, Ama Z. S. Rohatiner, Francesco Lauria, Francesco Forconi, Nigel T. J. O’Connor, A P Haynes
Publikováno v:
British Journal of Haematology. 145:733-740
Hairy cell leukaemia (HCL) was first described 50 years ago. Median survival was then 4 years. The purine analogues, introduced in the 1980s, transformed this prognosis. We reviewed data retrospectively from 233 patients, treated with pentostatin (n